The price of palbociclib in medical insurance in 2023

After the original drug Palbociclib (Palbociclib) was launched in China, it has entered the scope of Class B medical insurance through the relevant policies of the National Medical Insurance Administration, but it is only reimbursed for patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer. Patients who do not meet the conditions can only purchase it at their own expense. The reimbursement ratio is different in different regions, and the price after reimbursement may be different.

Palbociclib is used to treat estrogen receptor-positive but HER2-negative breast cancer. Patients may be treated with palbociclib if their breast cancer has spread to the tissues and lymph nodes around the chest, neck, and substernal region (locally advanced breast cancer); has spread to other parts of the body such as the bones, lungs, liver, or brain (secondary breast cancer). Palbociclib is not currently used in early-stage (primary) breast cancer, although clinical trials are investigating whether this is useful. The starting dose of palbociclib is 125 mg, usually as a capsule.

The price of each box of domestic palbociclib original medicine may be more than 4,000 yuan. The price of palbociclib's original drug, 125mg*21 capsules, per box sold overseas may be more than RMB 10,000 (the price may fluctuate due to exchange rates). There are also generic palbociclib drugs produced in other countries. The price of 125mg*21 tablets produced by Bangladesh pharmaceutical factory may be around 900 yuan per box (the price may fluctuate due to the exchange rate), which is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.